scholarly journals High KIFC1 expression is associated with poor prognosis in prostate cancer

2021 ◽  
Vol 38 (5) ◽  
Author(s):  
Laurie G. Kostecka ◽  
Athen Olseen ◽  
KiChang Kang ◽  
Gonzalo Torga ◽  
Kenneth J. Pienta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Poor Prognosis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Ploidy Levels ◽  
Free Survival ◽  
Metastatic Lesions ◽  
High Tumor Stage ◽  
High Ploidy ◽  
Kinesin Family

AbstractKinesins play important roles in the progression and development of cancer. Kinesin family member C1 (KIFC1), a minus end-directed motor protein, is a novel Kinesin involved in the clustering of excess centrosomes found in cancer cells. Recently KIFC1 has shown to play a role in the progression of many different cancers, however, the involvement of KIFC1 in the progression of prostate cancer (PCa) is still not well understood. This study investigated the expression and clinical significance of KIFC1 in PCa by utilizing multiple publicly available datasets to analyze KIFC1 expression in patient samples. High KIFC1 expression was found to be associated with high Gleason score, high tumor stage, metastatic lesions, high ploidy levels, and lower recurrence-free survival. These results reveal that high KIFC1 levels are associated with a poor prognosis for PCa patients and could act as a prognostic indicator for PCa patients as well.

scholarly journals GPX7 is Identified as a Novel Prognostic Indicator for Brain Lower Grade Glioma (LGG): Evidence from a Pan-Cancer Analysis

2021 ◽  
Author(s):  
Qianqian Zhao ◽  
Yin Yang ◽  
Luyu Zhang ◽  
Yingying Wang ◽  
Tianpei Wang ◽  
...  
Keyword(s):  
Glutathione Peroxidase ◽  
Poor Prognosis ◽  
Enrichment Analysis ◽  
Prognostic Indicator ◽  
Lower Grade ◽  
Free Survival ◽  
Multiple Tumors ◽  
Expression Levels ◽  
Lower Grade Glioma ◽  
Pan Cancer

Abstract Background: Glutathione peroxidase-7 (GPX7), a newly discovered non-selenium-containing protein with glutathione peroxidase activity, is located near the endoplasmic reticulum. Various studies have reported the involvement of GPX7 in cancer disease progression. However, the expression patterns of GPX7 and its prognostic potential have not been evaluated from a pan-cancer perspective. Moreover, the relationship between GPX7 and prognosis in Brain Lower Grade Glioma (LGG) patients remains unclear.Methods: Expression levels of GPX7 were evaluated using the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis (GEPIA2) were used to evaluate the effect of GPX7 on clinical prognosis in TCGA tumors. Correlations between GPX7 and cancer immune infiltrates were investigated using the Tumor Immune Estimation Resource (TIMER) site and Estimating the Proportions of Immune and Cancer cells (EPIC) algorithm. In addition, the GEPIA2 and STRING websites were used for enrichment analysis of GPX7-related genes. Finally, we constructed a prognostic Nomogram for LGG to verify the overall survival (OS) outcomes of patients.Results: GPX7 was found to be overexpressed in multiple tumors. Elevated expression levels of GPX7 were associated with poor prognosis regarding OS, disease-free survival (DFS) and progression-free survival (PFS) of LGG patients (OS Hazard ratio (HR) = 1.044, p < 0.0001; DFS HR = 1.035, p < 0.0001; PFS HR = 1.045, p < 0.0001). Concordance index (C-index) of the nomogram for LGG was 0.845 (95% CI, 0.825 to 0.865; p < 0.001). The nomogram exhibited a better predictability. In addition, GPX7 expression and the abundance of Cancer-associated fibroblasts (CAFs) were positively correlated in most cancer types. Enrichment analysis revealed that GPX7 may be involved in the glutathione derivative biosynthetic and glutathione metabolic biological processes.Conclusion: GPX7 was found to be upregulated in multiple tumors, which was correlated with poor prognosis in LGG. Therefore, GPX7 is a potential prognostic indicator for LGG. There is a strong correlation between GPX7 expression levels and glutathione metabolic pathways. GPX7 holds promise for the use of glutathione metabolism for guided therapy in cancer patients.

scholarly journals Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Xi Zhou ◽  
Yanghua Fan ◽  
Yu He ◽  
Anna Mou ◽  
Fu Wang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Noncoding Rna ◽  
Histological Grade ◽  
Meta Analysis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Poor Overall Survival ◽  
Multiple Cancers ◽  
Hazard Ratios ◽  
High Tumor Stage

Background. Long noncoding RNA gastric cancer highly expressed transcript 1 (lncRNA GHET1) is often reported to be abnormally expressed in multiple cancers, but the situation is different in different cancers. Therefore, a meta-analysis is necessary to clarify the value of lncRNA GHET1 as a prognostic indicator in cancer. Methods. Relevant research studies on lncRNA GHET1 and cancer were retrieved from three electronic literature databases of Web of Science, PubMed, and OVID. Meanwhile, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between lncRNA GHET1 expression and survival of cancer patients. The odds ratios (ORs) and 95% CIs were calculated to assess the association of lncRNA GHET1 expression with pathological parameters of cancer patients. Results. The meta-analysis included a total of 11 studies involving 714 cancer patients. The pooled HR suggests that high lncRNA GHET1 expression is associated with poor overall survival. In addition, high expression of lncRNA GHET1 was found to be associated with larger tumor size, poor histological grade, high tumor stage, lymph node metastasis, and distant metastasis. Conclusions. High lncRNA GHET1 expression can predict poor survival and pathological parameters. And lncRNA GHET1 could serve as a new indicator in multiple cancers.

Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.

1994 ◽  
Vol 12 (7) ◽  
pp. 1402-1407 ◽  
Author(s):  
B Chauvet ◽  
C Félix-Faure ◽  
N Lupsascka ◽  
J Fijuth ◽  
Y Brewer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Prostate Specific Antigen ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Tumor Stage ◽  
Localized Prostate Cancer ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Rate Of Decline

PURPOSE To assess the prognostic significance of serum prostate-specific antigen (PSA) in the monitoring of patients with localized prostate cancer treated with primary radiation therapy, we analyzed the data from 179 patients treated at our institution between 1987 and 1990. PATIENTS AND METHODS One hundred seventy-nine previously untreated patients received radiation at 69 Gy to the prostate with curative intent for prostate adenocarcinoma. The median follow-up duration is now 41 months. PSA levels were measured before radiotherapy and then evaluated periodically. RESULTS Baseline levels were greater than 4 ng/mL in 83% of cases and were significantly correlated with clinical tumor stage (P = .002). Six months after completion of therapy, PSA values had returned to normal in 53% of the patients with initially elevated values. At the time of analysis, 32 patients have relapsed, including three of 30 patients (10%) with normal initial and 6-month values, five of 79 patients (6%) with initially elevated but normal 6-month values, and 24 of 69 patients (35%) with persistently elevated PSA levels at 6 months. Actuarial 4-year relapse-free survival was significantly correlated with initial and 6-month PSA values (84% in patients with normal 6-month values v 60% in patients with persistently elevated levels). Furthermore, when the relative decline between initial and 6-month PSA values exceeded 50%, the crude rate of recurrence was 14% as opposed to 34% when it failed to exceed 50%. The 4-year relapse-free survival rates were 77% and 59%, respectively (P = .008). By multivariate analysis restricted to the patients with elevated baseline PSA levels, the rate of decline of PSA values reached the highest prognostic significance (P < .0001). Age at diagnosis, clinical tumor stage, and Gleason score only reached statistical significance in univariate analysis. CONCLUSION PSA values are of major prognostic significance in assessing the 4-year results of radical radiation therapy for localized prostate cancer. The rate of decline of PSA values is the strongest predictor of outcome and might help to identify a subset of patients with poorer prognosis who may benefit from early hormonal therapy.

scholarly journals Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer

2020 ◽  
Author(s):  
Azadeh khalvandi ◽  
Maryam Abolhasani ◽  
Zahra Madjd ◽  
Mehdi Shekarabi ◽  
Masoumeh Kourosh Arami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Poor Prognosis ◽  
Disease Free Survival ◽  
Immunohistochemical Analysis ◽  
Intraepithelial Neoplasia ◽  
Tissue Samples ◽  
Free Survival ◽  
Nuclear Expression ◽  
Formalin Fixed Paraffin Embedded

Abstract Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer- testis antigens and is common in various types of cancers. Due to its high immunogenicity and oncogenicity, it has been a candidate for cancer immunotherapy and used as a cancer vaccine in clinical trials of various types of cancers. In this study, for the first time, we performed immunohistochemical analysis to evaluate the expression of MAGE-A3 in 153 formalin-fixed paraffin-embedded prostate tissue samples including 112 cases of prostate cancer (PCa), 22 cases of benign prostatic hyperplasia (BPH) and 19 cases of high-grade prostatic intraepithelial neoplasia (HPIN). Both nuclear and cytoplasmic expressions of MAGE-A3 with different staining intensities were observed among the tissues. Increased expression of MAGE-A3 was significantly found in PCa tissues compared to both HPIN and BPH tissues (nuclear expression at P = 0.011, and cytoplasmic expression at p = 0.034; for both comparisons P < 0.0001, respectively). A significant correlation was observed between higher nuclear and cytoplasmic expressions of MAGE-A3 with Gleason score (P < 0.0001 and 0.006, respectively). Increased expression of MAGE-A3 was associated with shorter biochemical recurrence-free survival (BCR-FS) and disease-free survival (DFS) of patients (P = 0.042 and P = 0.0001, respectively). In multivariate analysis, nuclear expression of MAGE-A3 and Gleason score (≤ 7 vs > 7) were independent predictors of the DFS (both; P = 0.019). Nuclear expression of MAGE-A3 was also significantly related to BCR-FS (P = 0.015). MAGE-A3 can be considered as a valuable predictor for poor prognosis and an attractive option for vaccine immunotherapy in patients with PCa.

Nuclear and Cytoplasmic Expression of ErbB-4 in Prostate Cancer

2007 ◽  
Vol 22 (3) ◽  
pp. 181-185
Author(s):  
R. Ben-Yosef ◽  
D. Sarid ◽  
A. Vexler ◽  
G. Lidawi ◽  
M. Inbar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Lymph Node Involvement ◽  
Advanced Tumor Stage ◽  
Nuclear Staining ◽  
Free Survival ◽  
Advanced Tumor ◽  
Disease Free

Purpose To evaluate cytoplasmic and nuclear ErbB-4 expression in prostate cancer specimens and its association with outcome. Basic procedures Specimens of 50 prostate cancer patients were investigated for ErbB-4 overexpression using immunohistochemistry staining. Cytoplasmic and nuclear staining was graded as 0–3 according to its intensity. The prognostic parameters were tumor stage, PSA level, Gleason score, probability of positive lymph nodes (Partin's tables and Roach equation), and 5-year disease free survival (Kattan nomogram). Main findings Overexpression of ErbB-4 (≥1) was detected in 30 (60%) patients and overexpression using cytoplasmic and nuclear staining was ≥2 in 19 (38%) and 17 (34%) patients, respectively. In only one third of the specimens was there any similarity between the 2 types of staining. Advanced tumor stage, high pretreatment PSA levels and high Gleason scores were evenly distributed among the patients with low (≤1) and intermediate/high (≥2) ErbB-4 expression. The probability of lymph node involvement and 5-year disease free survival were similar in both types of staining. Principal conclusions ErbB-4 was overexpressed (cytoplasmic and nuclear staining) in approximately one third of prostate cancer patients. The rate of similarity between the 2 staining types was only 33%: overexpression was evenly distributed among intermediate/high and low risk prostate cancer patients with both staining methods.

High Expression of Ubiquitin C-terminal Hydrolase L1 Is Associated With Poor Prognosis in Endometrial Cancer Patients

2018 ◽  
Vol 28 (4) ◽  
pp. 675-683 ◽  
Author(s):  
Kohshiro Nakao ◽  
Takashi Hirakawa ◽  
Hiroto Suwa ◽  
Kayoko Kogure ◽  
Sadatomo Ikeda ◽  
...  
Keyword(s):  
Overall Survival ◽  
Endometrial Cancer ◽  
Protein Expression ◽  
Messenger Rna ◽  
Poor Prognosis ◽  
Disease Free Survival ◽  
Rna Expression ◽  
Free Survival ◽  
Metastatic Lesions ◽  
Disease Free

ObjectiveThe ubiquitin C-terminal hydrolase L1 (UCHL1) plays a key role in tumor invasion and metastasis. Ubiquitin C-terminal hydrolase L1 is overexpressed in various cancers and reported to be correlated with a poor prognosis. The objective of this study was to determine the prognostic significance of UCHL1 in endometrial cancer.MethodsThe expression of UCHL1 in endometrial cancer was assessed using quantitative reverse transcription polymerase chain reaction and immunohistochemistry in 56 and 215 resected tumor specimens, respectively.ResultsThe 4-year survival rates of the high UCHL1 messenger RNA expression group and high UCHL1 protein expression group were 78% and 71%, respectively, compared with 96% and 95% for the low UCHL1 messenger RNA expression group and low UCHL1 protein expression group, respectively. Kaplan-Meier and log-rank tests indicated a significant correlation between expression of UCHL1 and disease-free survival and overall survival. Moreover, multivariate stepwise Cox proportional hazard regression model analysis showed that UCHL1 was a significant independent marker for predicting a poor disease-free survival and overall survival. In 43 patients with metastatic lesions, immunohistochemical analysis of metastatic lesions revealed that the recurrence rate and mortality rate were 62% and 41%, respectively, in 29 UCHL1-positive patients and 36% and 29%, respectively, in 14 UCHL1-negative patients.ConclusionsThe results of this study suggest that high UCHL1 expression is a strong marker of poor prognosis of endometrial cancer. Furthermore, we suggest that UCHL1 may be involved in the development of distant metastasis in endometrial cancer.

Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 124-124
Author(s):  
Sarah Minner ◽  
Antje Krohn ◽  
Hueseyin Sirma ◽  
Ronald Simon ◽  
Markus Graefen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Poor Prognosis ◽  
Statistical Power ◽  
Tumor Stage ◽  
Nuclear Accumulation ◽  
Cancer Tissue ◽  
Positive Staining ◽  
Advanced Tumor Stage ◽  
Advanced Tumor ◽  
Psa Recurrence

124 Background: We have previously shown that nuclear accumulation of p53 is rare in prostate cancer but strongly linked to early biochemical recurrence (Schlomm et al., Modern Pathology, 2008). The current study was designed to study the association between ERG fusion and p53 in a large series of prostate cancers. Methods: A prostate cancer tissue microarray (TMA) was constructed from 4,699 radical prostatectomie specimens with histological, pathological, and clinical follow-up data. Immunohistochemistry was applied to detect nuclear p53 accumulation as a marker for defective p53 and to detect ERG expression as a surrogate for ERG gene fusion. Results: Nuclear accumulation of p53 was detected in 62/3,667 (1.7%) analyzable tissue spots. Positive staining was significantly linked to advanced tumor stage (p<0.0001), high Gleason score (p<0.0001), presence of lymph node metastases (p=0.0005), and early PSA recurrence (p<0.0001) in all cancers. ERG expression was found in 1,990/4,266 (46.6%) analyzable cancers, but was unrelated to tumor phenotype or patient prognosis. Results of both p53 and ERG were available from 3,392 tumors. Presence of nuclear p53 staining was linked to ERG fusion positive cancers: 40 (2.7%) of 1,491 ERG-positive cancers, but only 20 (1.1%) of 1,901 ERG-negative tumors showed nuclear p53 staining (p=0.0004). A Kaplan-Meier survival analysis of p53 in the subsets of 1,699 ERG positive and 1,280 ERG negative cancers revealed that nuclear p53 accumulation was strongly linked to early PSA recurrence in both subsets (p<0.0001 each). Conclusions: These data demonstrate that the poor prognosis of prostate cancer patients with nuclear p53 accumulation is independently from the ERG fusion status, but suggest a distinct biological role of p53 inactivation in ERG fusion positive cancers. The very high number of prostate cancer samples included in the TMA used in this study allows for analysis of rare events such as p53 alterations with high statistical power.

1495: Elevated Expression of Tumor-Associated Macrophages is Associated with Poor Prognosis of Human Prostate Cancer

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Hitoshi Takayama ◽  
Norio Nonomura ◽  
Daizo Oka ◽  
Masahiro Shiba ◽  
Yasuyuki Arai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Poor Prognosis ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Tumor Associated Macrophages ◽  
Elevated Expression
Sign in / Sign up

Export Citation Format

Share Document